Zynex (ZYXI)
(Delayed Data from NSDQ)
$11.21 USD
+0.27 (2.47%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $11.20 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.21 USD
+0.27 (2.47%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $11.20 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
Zacks News
Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -76.47% and 12.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q3 Earnings Match Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0% and 0.84%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 125% and 1.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 300% and 6.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 5.26% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Does Zynex Inc. (ZYXI) Have the Potential to Rally 65% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Zynex Inc. (ZYXI) points to a 65.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zynex Inc. (ZYXI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 8.33% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q1 Earnings Miss Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -40% and 0.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 21.05% and 1.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q3 Earnings Top Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 30.77% and -1.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Zynex Inc. (ZYXI) Could Rally 87%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Zynex Inc. (ZYXI) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zynex Inc. (ZYXI) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and -0.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
Zynex Inc. (ZYXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zynex Inc. (ZYXI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0.00% and 2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex (ZYXI) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zynex's (ZYXI) April orders down approximately 35% from the January and February average. This may have impacted its Q2 earnings.
Agios Gets Orphan Drug Tag for Mitapivat to Treat Thalassemia
by Zacks Equity Research
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
by Zacks Equity Research
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
Top Stock Picks for Week of May 11, 2020
by Panel Of Zacks Experts
Two Medical Products Stocks with Recent Price Strength.
5 Stocks With Recent Price Strength Amid Disappointing Data
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Trump Pushes for US-Made Medical Products: 4 Winners
by Ritujay Ghosh
An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.
Top Ranked Momentum Stocks to Buy for May 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 5th
New Strong Buy Stocks for May 4th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Will Zynex Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Zynex
Zynex Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Zynex has been struggling lately, but the selling pressure may be coming to an end soon.